Compare Sanofi SA (SNY) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs United Airlines Holdings Inc — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while United Airlines Holdings Inc trades at $107.56 (market cap $35.13B). The key difference: Sanofi SA is far larger — about 3× United Airlines Holdings Inc's market cap, and Sanofi SA pays a 5.61% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals.
| SNY | UAL | |
|---|---|---|
Market Cap | $104.06B | $35.13B |
Sector | Health | Industrials |
52-Week High | $52.34 | $136.11 |
52-Week Low | $41.33 | $85.21 |
Enterprise Value | $124.09B | $52.16B |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
United Airlines (UAL) trades at $108.24, down 2.82% today, with a bearish technical signal but strong fundamentals including a P/E of 10.13 and net income margin of 5.56%. The company has beaten EPS estimates for three consecutive quarters and announced its largest international expansion, adding 10 new routes for 2027. Cash flow trends show volatility, with 2025 net cash flow negative at -$2.86 billion but projected to turn positive in 2026.
The outlook is mixed: analyst consensus is strongly bullish with a $168.96 price target, but high jet fuel costs and geopolitical risks pose headwinds. Earnings growth and international expansion are key catalysts, while debt levels and operational efficiency remain areas to watch for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
